Upregulated Expression of Actin-Like 6A is a Risk Factor Affecting the Prognosis of Pancreatic Cancer

Figures & data

Table 1 The Number of Patients in Different Scores Based on Immunohistochemistry Staining

Scores	No. of Patients (%)
	Tumor	Normal
1	11 (18.3)	17 (28.3)
2	7 (11.7)	21 (35.0)
3	1 (1.7)	6 (10.0)
4	7 (11.7)	8 (13.3)
6	24 (40.0)	8 (13.3)
8	5 (8.3)	0 (0.0)
9	2 (3.3)	0 (0.0)
12	3 (5.0)	0 (0.0)

Figure 1 Expression of ACTL6A in PC and normal tissues. (A) Differential expression of Actl6a mRNA between pancreatic tumor and normal tissues. (B) Immunohistochemical results of typical normal tissues and PC tissues with different staining intensities. (C) Differential expression of ACTL6A between pancreatic tumor and normal tissues. (D) ACTL6A represented a moderate diagnostic value. The ROC of pancreatic cancer samples and normal tissues. (E) ROC for the diagnostic efficiency of ACTL6A, serum CEA, and serum CA19–9. *p<0.05.

Abbreviations: ACTL6A, actin like 6A; PC, pancreatic cancer; ROC, receiver operating characteristic curves; CA19–9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen.

Table 2 Relationships Between the Expression Level of ACTL6A and the Clinicopathological Characteristics of PC Patients

Characteristics	No. of Patients	Expression of ACTL6A		p value
		High	Low
Age(years)				0.151
<65	26	12	14
≥65	34	22	12
Sex				0.889
Male	34	15	19
Female	26	11	15
Tumor site				0.651
Head	32	19	13
Other^a	28	15	13
Grade				0.713
Well/moderately	40	22	18
Poorly/undifferentiated	20	12	8
T stage				0.505
T1+T2	26	16	10
T3+T4	34	18	16
N stage				0.930
N0	25	14	11
N1+N2	35	20	15
M stage				0.339
M0	57	31	26
M1	3	3	0
TNM stage				0.702
I	13	7	6
II–IV	47	27	20
LVSI				0.025
Yes	26	19	7
No	34	15	19

Note: ^aPancreatic body and tail.

Abbreviations: ACTL6A, actin-Like 6A; PC, pancreatic cancer; LVSI, lymphovascular space invasion.

Figure 2 (A) Kaplan–Meier curves of overall survival in PC patients with high and low Actl6a mRNA expression. (B) Kaplan–Meier curves of overall survival in PC patients with high and low ACTL6A expression.

Abbreviations: ACTL6A, actin like 6A; PC, pancreatic cancer.

Table 3 Univariate and Multivariate Analysis of Clinicopathological Characteristics Affecting Prognosis of Patients with PC

Characteristics	Univariate			Multivariate
	HR	95% CI	p value	HR	95% CI	p value
ACTL6A
Low		Ref			Ref
High	1.899	1.056–3.415	0.032	1.810	1.010–3.243	0.046
Age(years)
<65		Ref
≥65	1.053	0.600–1.848	0.857
Sex
Male		Ref
Female	0.646	0.365–1.141	0.132
Tumor site
Head		Ref
Other^a	0.736	0.422–1.284	0.281
Grade
Well/moderately		Ref			Ref
Poorly/undifferentiated	2.198	1.231–3.924	0.008	2.021	1.127–3.624	0.018
T stage
T1+T2		Ref			Ref
T3+T4	1.737	0.973–3.103	0.062	1.575	0.880–2.819	0.126
N stage
N0		Ref
N1+N2	1.442	0.816–2.550	0.208
M stage
M0		Ref
M1	2.205	0.673–7.221	0.191
TNM stage
I		Ref
II–IV	1.759	0.853–3.626	0.126
LVSI
No		Ref
Yes	1.434	0.822–2.501	0.204

Note: ^aPancreatic body and tail.

Abbreviations: ACTL6A, actin-Like 6A; PC, pancreatic cancer; LVSI, lymphovascular space invasion.

Figure 3 Forest plot of univariate (A) and multivariate (B) cox regression.

Abbreviations: ACTL6A, actin like 6A; PC, pancreatic cancer; LVSI, lymphovascular space invasion.